FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / a a la i a a 4 a a	D C	20540
Vashington,	D.C.	20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Riva Alessandro  (Last) (First) (Middle)  C/O CENTURY THERAPEUTICS, INC.  25 N 38TH STREET, 11TH FLOOR  (Street)  PHILADELPHIA PA 19104				- 3. D 06/2 4. If	2. Issuer Name and Ticker or Trading Symbol Century Therapeutics, Inc. [ IPSC ]  3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)  Rule 10b5-1(c) Transaction Indication						6. Ir	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner Officer (give title Delow)      6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City)	(S	,	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  Table II - Derivati				nsaction h/Day/Yea	Execution Date, if any (Month/Day/Year)    Execution Date, if any (Month/Day/Year)   Transaction Code (Instr. 8)   Disposed Of (D) (II S)			(A) or (D)	r Price	5. Amou Securitie Benefici Owned F Reporter Transact (Instr. 3	nt of 6.es Feally (Discounting discounting time)	orm: Direct 0) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Derivative Conversion Date Execution Date, T Generate (Month/Day/Year) Factor Date of Execution Date o				ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expirat Date	tion	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$3.19	06/27/2023		A		44,000		(1)	06/27/2	2024	Common Stock	44,000	\$0.00	44,000	D	

## Explanation of Responses:

1. The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

/s/ Michael Diem, Attorney-in-Fact

06/29/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.